<DOC>
	<DOCNO>NCT00393679</DOCNO>
	<brief_summary>The main objective compare safety efficacy 4 artemisinin-based combination ( ACT ) [ amodiaquine-artesunate ( AQ+AS ) , dihydroartemisinin-piperaquine ( DHAPQ ) , artemether-lumefantrine ( AL ) chlorproguanil/dapsone plus artesunate ] single repeat treatment uncomplicated malaria child . Safety determine register adverse event grade , laboratory , vital sign evaluation . Their incidence compare different study arm . TO BE NOTED : follow GlaxoSmithKline decision discontinue clinical development fixed-doses combination Lapdap ( Chlorproguanil-Dapsone ) artesunate , Lapdap plus Artesunate arm immediately discontinue study , 17th February 2008 . A formal amendment submit concerned ECs competent authority . The lead EC approve amendment 2nd June 2008 . TO BE NOTED : since batch study drug DHAPQ expire end October 2008 , unavailability new batch DHAPQ manufacturer , recruitment DHAPQ arm discontinue 30th October 2008 . A formal amendment submit concerned ECs competent authority .</brief_summary>
	<brief_title>Evaluation 4 Artemisinin-based Combinations Treating Uncomplicated Malaria African Children</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Males Females age 6 month 59 month inclusive . In site CDA test recruited child age 12 month 59 month inclusive ( arm discontinue 17th February 2008 ) . This criterion apply recruitment first follow . For second follow , child include first follow eligible , regardless age . Body weight 5 Kg . Microscopically confirm , monoinfection Plasmodium falciparum ( parasitaemia ≥ 2,000/μL 200,000/μL ) . Fever ( axillary temperature ≥ 37.5°C ) history fever previous 24 hour . Haemoglobin value ≥ 7.0 g/dl ; Signed ( thumbprinted whenever parents/guardians illiterate ) inform consent parent guardian . Note inform consent ask recruitment cover whole period study , include second active follow passive case detection . Parents ' guardian ' willingness ability comply study protocol duration trial . Participation investigational drug study ( antimalarial others ) previous 30 day . Known hypersensitivity study drug . Severe malaria . Danger sign : able drink breastfeed , vomit ( &gt; twice 24hours ) , recent history convulsion ( &gt; 1 24h ) , unconscious state , unable sit stand . Presence intercurrent illness condition ( cardiac , renal , hepatic disease ) judgement investigator would place subject undue risk interfere result study , include know G6PD deficiency . Severe malnutrition ( defined weight height &lt; 70 % median NCHS/WHO reference ) . Ongoing prophylaxis drug antimalarial activity cotrimoxazole prevention Pneumocystis carinii pneumonia child bear HIV+ woman .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Children 6-59 month</keyword>
	<keyword>P.falciparum</keyword>
	<keyword>Haemoglobin</keyword>
	<keyword>Informed consent</keyword>
	<keyword>ACT</keyword>
</DOC>